Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

• Jeong Hun Kim,
• Won Suk Lee,
• Seung Joon Lee,
• Hannah Yang,
• Hong Jae Chon,
• Chan Kim,
• Jin Hyoung Kim,
• Byung cheol Ahn,
• Dong Sung Kim,
• Yoonki Heo,
• Eun-Jin Go,
• Jung Sun Yum

Affiliations

Jeong Hun Kim

Department of Biomedical Science, CHA University, Seongnam, Gyeonggi-do, Korea (the Republic of)

Won Suk Lee

Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)

Seung Joon Lee

Department of Biomedical Science, CHA University, Seongnam, Gyeonggi-do, Korea (the Republic of)

Hannah Yang

Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)

Hong Jae Chon

Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)

Chan Kim

instructor

Jin Hyoung Kim

Youth Bio Global, Ltd, Seoul, Republic of Korea

Byung cheol Ahn

4CHA Vaccine Institute, Seoul, Korea, Republic of

Dong Sung Kim

Laboratory of Translational Immuno-Oncology, Seongnam, Gyeonggi-do, Korea (the Republic of)

Yoonki Heo

CHA Vaccine Institute, Seongnam, Gyeonggi-do, Korea (the Republic of)

Eun-Jin Go

Laboratory of Translational Immuno-Oncology, Seongnam, Gyeonggi-do, Korea (the Republic of)

Jung Sun Yum

CHA Vaccine Institute, Seongnam, Gyeonggi-do, Korea (the Republic of)